$ABOS: Acumen Pharmaceuticals Phase 2 ALTITUDE-AD Trial Misses Primary Endpoi

$ABOS

$ABOS – Acumen Pharmaceuticals Phase 2 ALTITUDE-AD Trial Misses Primary Endpoint

Acumen Pharmaceuticals, Inc.

2026-10-30 00:00:00 UTC · SEC_8K · All $ABOS

?? Negative AI Sentiment (-9.0 / 10)

Sabirnetug (ACU193) Phase 2 ALTITUDE-AD trial failed to meet primary endpoint of cognitive decline (iADRS) vs placebo at 18 months.
Failure observed across both tested doses (35 mg/kg and 50 mg/kg).
Highly negative clinical outcome for the company's lead Alzheimer's candidate.